Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2018 Dec;68(6):2428-2430.
doi: 10.1002/hep.30069. Epub 2018 Nov 7.

Fibroblast Growth Factor Receptor Inhibition for Cholangiocarcinoma: Looking Through a Door Half-Opened

Sumera I Ilyas  1 , Gregory J Gores  1
Affiliations
Comment

Fibroblast Growth Factor Receptor Inhibition for Cholangiocarcinoma: Looking Through a Door Half-Opened

Sumera I Ilyas et al. Hepatology. 2018 Dec.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
FGFR2 gatekeeper mutations prevent binding of BGJ398. The gatekeeper residue is present in the ATP-binding pocket of FGFR. BGJ398 binds to the gatekeeper residue with resultant inhibition of oncogenic signaling (left panel). Mutation of the gatekeeper residue inhibits binding of BGJ398 and oncogenic signaling remains on (right panel).
See this image and copyright information in PMC

Comment on

  • Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.
    Javle M, Lowery M, Shroff RT, Weiss KH, Springfeld C, Borad MJ, Ramanathan RK, Goyal L, Sadeghi S, Macarulla T, El-Khoueiry A, Kelley RK, Borbath I, Choo SP, Oh DY, Philip PA, Chen LT, Reungwetwattana T, Van Cutsem E, Yeh KH, Ciombor K, Finn RS, Patel A, Sen S, Porter D, Isaacs R, Zhu AX, Abou-Alfa GK, Bekaii-Saab T. Javle M, et al. J Clin Oncol. 2018 Jan 20;36(3):276-282. doi: 10.1200/JCO.2017.75.5009. Epub 2017 Nov 28. J Clin Oncol. 2018. PMID: 29182496 Free PMC article. Clinical Trial.

References

    1. Rizvi S, Khan SA, Hallemeier CL, et al. Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018;15:95–111. - PMC - PubMed
    1. Graham RP, Barr Fritcher EG, Pestova E, et al. Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma. Hum Pathol. 2014;45:1630–8. - PubMed
    1. Wu YM, Su F, Kalyana-Sundaram S, et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov. 2013;3:636–47. - PMC - PubMed
    1. Mazzaferro V, El-Rayes BF, Cotsoglou C, et al. ARQ 087, an oral pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced intrahepatic cholangiocarcinoma (iCCA) with FGFR2 genetic aberrations. J Clin Oncol. 2017;35:4017.
    1. Nogova L, Sequist LV, Perez Garcia JM, et al. Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1–3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I. Dose-Escalation and Dose-Expansion Study. J Clin Oncol. 2016 JCO2016672048. - PMC - PubMed

Publication types